The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 25, 2018
Filed:
Mar. 24, 2015
Temple University-of the Commonwealth System of Higher Education, Philadelphia, PA (US);
The Johns Hopkins University, Baltimore, MD (US);
Salim Merali, Bryn Mawr, PA (US);
Carlos A. Barrerro, Philadelphia, PA (US);
Kamel Khalili, Bala Cynwyd, PA (US);
Jay Rappaport, Somers Point, NJ (US);
Norman J. Haughey, Baltimore, MD (US);
Ned Sacktor, Baltimore, MD (US);
Temple University—Of The Commonwealth System of Higher Education, Philadelphia, PA (US);
The Johns Hopkins University, Baltimore, MD (US);
Abstract
Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.